Arinna Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
- Paid Up Capital ₹ 13.06 Cr
- Company Age 11 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.00 M
- Satisfied Charges ₹ 6.15 Cr
- Revenue Growth 7.75%
- Profit Growth -19.93%
- Ebitda 1141.58%
- Net Worth 11.28%
- Total Assets -0.58%
About Arinna Lifesciences
Arinna Lifesciences Limited (ALL) is a leading Public Limited Indian Non-Government Company incorporated in India on 29 August 2013 and has a history of 11 years and five months. Its registered office is in Ahmedabad, Gujarat, India.
The Corporate was formerly known as Arinna Lifesciences Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 13.06 Cr.
The company currently has active open charges totaling ₹9.00 M. The company has closed loans amounting to ₹6.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Arinna Lifesciences Limited India are Subramaniam Iyer as CFO and Smit Rupareliya as Company Secretary. Siddharth Shah, Shankar Gopalakrishnan, Vivek Seth, and Two other members serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230GJ2013PLC076619
- Company No.
076619
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2013
- Date of AGM
29 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Arinna Lifesciences Limited offer?
Arinna Lifesciences Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antiepileptic Drugs, Pharma Ingredients & Raw Materials, Nervous System and Antipsychotic API, Psychotherapeutic Agents, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Arinna Lifesciences?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Vivek Seth ![]() | Managing Director | 29-Aug-2013 | Current |
Subramaniam Iyer | CFO | 17-May-2022 | Current |
Smit Rupareliya | Company Secretary | 24-Apr-2024 | Current |
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Siddharth Shah ![]() | Director | 23-Apr-2015 | Current |
Rohit Mantri ![]() | Nominee Director | 03-May-2016 | Current |
Shankar Gopalakrishnan ![]() | Director | 23-Apr-2015 | Current |
Shilpa Seth ![]() | Director | 29-Aug-2013 | Current |
Financial Performance of Arinna Lifesciences.
Arinna Lifesciences Limited, for the financial year ended 2024, experienced modest growth in revenue, with a 7.75% increase. The company also saw a substantial fall in profitability, with a 19.93% decrease in profit. The company's net worth Soared by an impressive increase of 11.28%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Arinna Lifesciences?
In 2024, Arinna Lifesciences had a promoter holding of 38.16% and a public holding of 61.86%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹0.90 Cr
₹6.15 Cr
Charges Breakdown by Lending Institutions
- Others : 0.90 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
06 Jan 2025 | Others | ₹9.00 M | Open |
01 Apr 2021 | Axis Bank Limited | ₹3.00 Cr | Satisfied |
26 Feb 2018 | Axis Bank Limited | ₹3.15 Cr | Satisfied |
How Many Employees Work at Arinna Lifesciences?
Arinna Lifesciences has a workforce of 321 employees as of Feb 18, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Arinna Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arinna Lifesciences's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.